Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance
- PMID: 30204025
- DOI: 10.1177/1740774518770661
Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance
Abstract
Background Well-designed phase II trials must have acceptable error rates relative to a pre-specified success criterion, usually a statistically significant p-value. Such standard designs may not always suffice from a clinical perspective because clinical relevance may call for more. For example, proof-of-concept in phase II often requires not only statistical significance but also a sufficiently large effect estimate. Purpose We propose dual-criterion designs to complement statistical significance with clinical relevance, discuss their methodology, and illustrate their implementation in phase II. Methods Clinical relevance requires the effect estimate to pass a clinically motivated threshold (the decision value (DV)). In contrast to standard designs, the required effect estimate is an explicit design input, whereas study power is implicit. The sample size for a dual-criterion design needs careful considerations of the study's operating characteristics (type I error, power). Results Dual-criterion designs are discussed for a randomized controlled and a single-arm phase II trial, including decision criteria, sample size calculations, decisions under various data scenarios, and operating characteristics. The designs facilitate GO/NO-GO decisions due to their complementary statistical-clinical criterion. Limitations While conceptually simple, implementing a dual-criterion design needs care. The clinical DV must be elicited carefully in collaboration with clinicians, and understanding similarities and differences to a standard design is crucial. Conclusion To improve evidence-based decision-making, a formal yet transparent quantitative framework is important. Dual-criterion designs offer an appealing statistical-clinical compromise, which may be preferable to standard designs if evidence against the null hypothesis alone does not suffice for an efficacy claim.
Keywords: Clinical relevance; GO/NO-GO; dual-criterion; evidence; operating characteristics; phase II design; proof-of-concept; statistical significance.
Similar articles
-
Bayesian optimal phase II designs with dual-criterion decision making.Pharm Stat. 2023 Jul-Aug;22(4):605-618. doi: 10.1002/pst.2296. Epub 2023 Mar 5. Pharm Stat. 2023. PMID: 36871961
-
Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.J Biopharm Stat. 2019;29(1):189-202. doi: 10.1080/10543406.2018.1489400. Epub 2018 Jul 3. J Biopharm Stat. 2019. PMID: 29969380
-
A Bayesian paradigm for decision-making in proof-of-concept trials.J Biopharm Stat. 2017;27(3):442-456. doi: 10.1080/10543406.2017.1289947. Epub 2017 Feb 6. J Biopharm Stat. 2017. PMID: 28166459
-
Integrated phase II/III clinical trials in oncology: a case study.Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22. Clin Trials. 2012. PMID: 23180870 Free PMC article. Review.
-
Group-sequential methods for adaptive seamless phase II/III clinical trials.J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335. J Biopharm Stat. 2011. PMID: 21516569 Review.
Cited by
-
A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.Biostatistics. 2022 Jan 13;23(1):328-344. doi: 10.1093/biostatistics/kxaa027. Biostatistics. 2022. PMID: 32735010 Free PMC article.
-
A randomised controlled phase II trial to examine the feasibility of using hyper-oxygenated fatty acids (HOFA) to prevent facial pressure injuries from medical devices among adults admitted to intensive care-A research protocol.Int Wound J. 2024 Oct;21(10):e70069. doi: 10.1111/iwj.70069. Int Wound J. 2024. PMID: 39353596 Free PMC article. Clinical Trial.
-
TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials.Stat Med. 2025 May;44(10-12):e70090. doi: 10.1002/sim.70090. Stat Med. 2025. PMID: 40390185 Free PMC article.
-
A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.Pharm Stat. 2021 Mar;20(2):212-228. doi: 10.1002/pst.2067. Epub 2020 Aug 29. Pharm Stat. 2021. PMID: 32860470 Free PMC article. Clinical Trial.
-
Evaluation of the Fill-it-up-design to use historical control data in randomized clinical trials with two arm parallel group design.BMC Med Res Methodol. 2024 Sep 9;24(1):197. doi: 10.1186/s12874-024-02306-2. BMC Med Res Methodol. 2024. PMID: 39251907 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
